Navigation Links
European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals

Worldwide COGENT-1 Study of CGT-2168 Expands to Europe; Focus on Reducing

Gastrointestinal Side Effects of Antiplatelet Therapy

MENLO PARK, Calif., June 16 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc. today announced that the first patient has been enrolled in Europe in the company's pivotal Phase 3 study of its novel combination medicine CGT-2168. The patient entered the COGENT-1 study at the Zadebie cardiology clinic in Skierniewice, Poland.


The study, which began in North America in January, is evaluating the antiplatelet medicine CGT-2168, a combination of clopidogrel (currently marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis as Plavix(R)) and a gastroprotectant (omeprazole) in a single pill. Developed by Cogentus, CGT-2168 is designed to provide cardiovascular benefits while reducing potentially serious gastrointestinal side effects commonly associated with dual antiplatelet therapy.

Antiplatelet therapy is an integral part of treating patients with acute coronary syndrome and has been shown to be effective in preventing major cardiovascular events. However, the combination of clopidogrel and aspirin is associated with gastrointestinal bleeding, which in some cases requires hospitalization and can even result in death.

"Millions of cardiac patients in Europe have benefited from antiplatelet therapy," said Gilles Montalescot, M.D., Ph.D., Professor of Cardiology at the Institut de Cardiologie, Pitie-Salpetriere Hospital in Paris. "It is important that our patients have access to innovative new treatment options that can enhance compliance with treatment and provide positive outcomes. We look forward to being part of the COGENT program."

Among the estimated 4,000 patients worldwide who will participate in the study, approximately half will receive clopidogrel and aspirin; the other half will receive CGT-2168 (clopidogrel plus omeprazole) and aspirin. Patients will be assessed regularly for any gastrointestinal side effects such as bleeding and ulcers as well as receive ongoing monitoring of their cardiovascular status.

"This is yet another important milestone for our company," said Cogentus Chairman and Chief Executive Officer Mark A. Goldsmith, M.D., Ph.D. "COGENT has been very well received by the medical community in North America, with strong enrollment. Now we will begin to gather important data from investigators in Europe and broaden the patient base of the study."


Cogentus Pharmaceuticals, Inc., of Menlo Park, CA, is a privately held specialty pharmaceutical company founded in 2006. Cogentus ( is committed to becoming a premier developer of innovative, fixed-dose combination prescription medicines serving unmet medical needs that drive significant commercial opportunities.

COGENT stands for Clopidogrel and the Optimization of Gastrointestinal Events Trial. In addition to North America and Europe, the COGENT program also will include patients in South America, where clinical sites are expected to come on line later this year.

Plavix(R) is a registered trademark of Sanofi-Aventis.

SOURCE Cogentus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. XTENT Announces European Regulatory Update
2. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
3. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
4. European Unions CHMP Issues Positive Opinion on Sugammadex
5. PLC Systems Announces Approval of First European Study to Evaluate RenalGuard(TM)
6. PRoFESS(R) Results Announced at XVII European Stroke Conference
7. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
8. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
9. European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina
10. More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
11. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
Post Your Comments:
(Date:11/25/2015)... 25, 2015 ... the "Global Brain Monitoring Devices Market ... --> ) has announced the ... Devices Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... WOODBURY, N.Y. , Nov. 25, 2015  Linden ... access and optimizing treatment outcomes for patients suffering from ... its request for a Temporary Restraining Order (TRO) enjoining ... between the two companies. --> ... aggressively pursuing all of its legal options. ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... an innovative online platform for mental health and wellness consultation, has collaborated with ... partnership will bridge the knowledge gap experienced by parents and bring advice from ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap and Dr. ... Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial ... conditions present in similar ways and require time-critical intervention to avoid large area heart ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity ... have come together on Thanksgiving Day to share the things that they are ... the Serenity Point YouTube channel, patients displayed what they wrote on index cards, ...
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced ... franchise owner, Somu now offers travelers, value and care based Travel Services, including ... sales, as well as, cabin upgrades and special amenities such as, shore excursions, ...
(Date:11/26/2015)... ... , ... PRMA Plastic Surgery is updating their record books yet again with ... flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... it’s an honor to have served all of these women.” , PRMA is one ...
Breaking Medicine News(10 mins):